HOME >> MEDICINE >> NEWS
New TB vaccine shows promise in HIV infection

for Hepatitis B. Parallel studies were also conducted on HIV- negative subjects.

"The multiple-dose course of the inactivated vaccine boosted immunity against TB both in those with HIV and those without TB," von Reyn said. "The vaccine was also safe and did not adversely affect the patients' underlying HIV infection."

The study served as the basis for a large-scale trial Dartmouth researchers have been conducting since 2001 in Dar es Salaam, Tanzania with Muhimbili Hospital Medical Center. The five-year $3 million NIH funded study is the only efficacy trial of a new TB vaccine currently under way in the world. The Tanzania trial will enroll more than 2000 HIV-infected patients to determine if the boosted immunity detected in the Finnish study actually reduces the risk of tuberculosis among HIV infected people in Tanzania at high risk of the disease.


'"/>

Contact: Andy Nordhoff
DMS.Communications@dartmouth.edu
603-650-1492
Dartmouth Medical School
6-Nov-2003


Page: 1 2

Related medicine news :

1. Pitt marks 50th anniversary of its Salk polio vaccine with reunion, scientific symposium
2. NIAID initiates trial of experimental avian flu vaccine
3. Study finds majority of women willing to accept cervical cancer vaccine for self and children
4. Invasive pneumonia and antibiotic resistance decreased after childhood vaccine introduced
5. Earlier use of prostate cancer vaccines urged by Hopkins scientists
6. Researchers close in on breast cancer vaccine
7. EuroVacc 02 HIV vaccine trial begins in February 2005
8. Varicella vaccine effective on chicken pox; Impact on herpes zoster unclear
9. Pathogen-mimicking vaccine as strategy for cancer therapy
10. HIV vaccine trial breaks ground for future research
11. First US kidney cancer vaccine trial underway at Columbia

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New vaccine shows promise HIV infection

(Date:6/18/2013)... New York (PRWEB) June 18, 2013 As ... both state and federal court, a new report has revealed ... than 70,000 U.S. Food & Drug Administration (FDA) adverse event ... to NewsChannel5 in Cleveland, Ohio, over 4.700 Mirena users have ... while more than 1,300 have reportedly experienced uterine perforations due ...
(Date:6/18/2013)... 2013 New York magazine named 145 physicians ... “Best Doctors” list, up from 129 last year and more ... issue also lists 52 additional doctors who serve at hospitals ... growth trajectory. The “Best Doctors” issue, which this year features ... print issue and is available online at http://www.nymag.com/bestdoctors . ...
(Date:6/18/2013)... York, N.Y., June 18, 2013 -- Lauren Sciences, ... novel V-Smart nanovesicle platform technology, announced today that ... in Drug Delivery with its V-Smart Platform, and ... report by MCD Group. , The ... of Start-ups and Emerging Companies ," features companies ...
(Date:6/18/2013)... their scheduled medical appointments and their disease under ... things clearly and knows them as a person, not ... "If people feel their doctor really knows them and ... best interests at heart and may be more likely ... Flickinger, M.D., M.P.H., a fellow in the Division of ...
(Date:6/18/2013)... officially declared June as Lesbian, Gay, Bisexual ... advances in civil rights, sexual minority youth ... than their heterosexual peers, according to the ... Missouri psychology graduate student recently published recommendation ... youth, which could help improve psychological functioning ...
Breaking Medicine News(10 mins):Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 3Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 3Health News:Respect may be the key to stopping patient 'no shows' 2Health News:Sexual minority youth need specialized treatment from therapists 2
(Date:6/17/2013)... 2013 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... at ENDO 2013, the Endocrine Society,s 95 th ... (synchronize) both melatonin and cortisol rhythms. This effect ... body clock and address the circadian desynchrony which ... (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal ...
(Date:6/17/2013)... DNAtrix Inc., experts in oncolytic virus development, today announced ... company,s lead product, DNX-2401, at the Replicating Oncolytic Virus ... on June 18, 2013. Dr. ... the field of oncolytic virus therapy, will present results ... OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS DNX-2401 (FORMERLY KNOWN AS ...
(Date:6/17/2013)... 2013 BioMed Realty Trust, Inc. (NYSE: ... declared a second quarter 2013 dividend of $0.235 per share ... dividend of $0.94 per common share. The ... stockholders of record at the close of business on June ... BioMed Realty delivers optimal real estate solutions for biotechnology ...
Breaking Medicine Technology:Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 3
Cached News: